1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The recombinant teriparatide injection market is evolving rapidly, driven by growing demand for anabolic osteoporosis care, innovative drug delivery systems, and increasing collaboration across global healthcare networks. Senior decision-makers are seeking targeted insight into competitive strategies, regulatory dynamics, and disruptive trends shaping this maturing sector.
Market Snapshot: Recombinant Teriparatide Injection Market
Spanning a dynamic international landscape, the recombinant teriparatide injection segment is underpinned by substantial clinical adoption, technology advances in delivery mechanisms, and a rising focus on patient-centric care pathways. The proliferation of user-friendly injection devices, improvements in molecular formulation, and the entry of biosimilars contribute to heightened competition and evolving value propositions. Reimbursement models and health policy frameworks continue to influence therapy accessibility and long-term market sustainability.
Scope & Segmentation
This market research delivers a comprehensive analysis across product categories, distribution networks, care environments, and regional geographies. Strategic segmentation empowers executives to tailor approaches to address specific end-user demands and optimize value delivery.
- Product Type: Pre-filled pens, single dose vials
- Distribution Channel: Hospital pharmacy, online pharmacy, retail pharmacy
- End User: Clinic, homecare setting, hospital
- Dosage Strength: 20 mcg, 40 mcg
- Indication: Glucocorticoid induced osteoporosis, hypoparathyroidism, severe osteoporosis
- Geographic Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, United Arab Emirates, Saudi Arabia, Russia, South Africa, others), Asia-Pacific (China, India, Japan, Australia, Thailand, Singapore, others)
- Key Companies: Eli Lilly and Company, Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Natco Pharma Limited, Viatris Inc., Wockhardt Limited, Cipla Limited, Lupin Limited, Intas Pharmaceuticals Limited
- Technology Landscape: Digital monitoring devices, modular bioreactor production, advanced molecular stabilization, patient support integration
Key Takeaways for Decision-Makers
- Rapid adoption of digital health tools in injection devices is optimizing therapy adherence and enabling remote clinical oversight.
- Diversification of packaging formats allows manufacturers to serve both institutional and home-based care settings while addressing safety and dosing needs.
- Strategic partnerships—spanning patient support organizations, academic consortia, and distribution networks—are critical in overcoming regional regulatory diversity and enhancing market reach.
- Emergence of biosimilars and alternative anabolic agents is intensifying competition, requiring active lifecycle management and innovation in service offerings.
- Multidisciplinary collaboration among endocrinologists, rheumatologists, and primary care specialists is driving improved care coordination and protocol standardization in real-world practice.
- Formulation advances and improvements in cold chain logistics facilitate wider accessibility, especially in regions with fragile healthcare infrastructure.
Tariff Impact on Cost Structure and Supply Chain Resilience
Recent United States tariff adjustments have significantly influenced raw material costs and logistics planning for injectable biopharmaceuticals. Manufacturers are adapting by diversifying suppliers, exploring regional contract manufacturing organization partnerships, and investing in vertical integration to mitigate cost volatility and sustain supply chain continuity.
Methodology & Data Sources
This report integrates primary and secondary research, featuring in-depth interviews with clinical experts and supply chain specialists, and a comprehensive review of regulatory filings, patent data, and real-world clinical evidence. Iterative cross-validation and expert peer review enhance the credibility and reliability of findings.
Why This Report Matters
- Enables executive teams to develop actionable, evidence-based strategies for maximizing recombinant teriparatide injection market access and commercial performance.
- Provides granular segmentation and regional analysis to inform resource allocation, investment prioritization, and targeted stakeholder engagement.
- Supports continuous innovation by highlighting disruptive trends in digital health, supply chain management, and collaborative research models.
Conclusion
Access to timely, detailed insights empowers stakeholders to anticipate disruptive forces, strengthen market presence, and deliver value to patients. This report offers a strategic foundation for navigating the evolving recombinant teriparatide injection landscape.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increased market penetration of biosimilar teriparatide formulations in European healthcare systems driven by pricing reforms
5.2. Development of novel sustained release teriparatide delivery systems to improve patient adherence and outcomes
5.3. Expansion of recombinant teriparatide indications into male osteoporosis and rare bone disorders following positive trial data
5.4. Implementation of digital health platforms for patient monitoring to enhance adherence to teriparatide injection regimens
5.5. Growing payer scrutiny and reimbursement challenges limiting teriparatide access in cost conscious healthcare markets
5.6. Strategies by key manufacturers to optimize manufacturing processes of recombinant teriparatide amid supply chain disruptions
5.7. Emerging market approvals in Asia Pacific driving competitive dynamics for teriparatide injection portfolios
5.8. Partnerships between pharma and telehealth providers to support remote administration of teriparatide injections
5.9. Long term safety and efficacy real world evidence influencing prescribing patterns of teriparatide among specialists
5.10. Introduction of combination therapy regimens integrating teriparatide with antiresorptive agents to maximize bone health
5.2. Development of novel sustained release teriparatide delivery systems to improve patient adherence and outcomes
5.3. Expansion of recombinant teriparatide indications into male osteoporosis and rare bone disorders following positive trial data
5.4. Implementation of digital health platforms for patient monitoring to enhance adherence to teriparatide injection regimens
5.5. Growing payer scrutiny and reimbursement challenges limiting teriparatide access in cost conscious healthcare markets
5.6. Strategies by key manufacturers to optimize manufacturing processes of recombinant teriparatide amid supply chain disruptions
5.7. Emerging market approvals in Asia Pacific driving competitive dynamics for teriparatide injection portfolios
5.8. Partnerships between pharma and telehealth providers to support remote administration of teriparatide injections
5.9. Long term safety and efficacy real world evidence influencing prescribing patterns of teriparatide among specialists
5.10. Introduction of combination therapy regimens integrating teriparatide with antiresorptive agents to maximize bone health
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. Recombinant Teriparatide for Injection Market, by Product Type
8.1. Introduction
8.2. Pre-Filled Pen
8.3. Single Dose Vial
8.2. Pre-Filled Pen
8.3. Single Dose Vial
9. Recombinant Teriparatide for Injection Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Recombinant Teriparatide for Injection Market, by End User
10.1. Introduction
10.2. Clinic
10.3. Homecare Setting
10.4. Hospital
10.2. Clinic
10.3. Homecare Setting
10.4. Hospital
11. Recombinant Teriparatide for Injection Market, by Dosage Strength
11.1. Introduction
11.2. 20 Mcg
11.3. 40 Mcg
11.2. 20 Mcg
11.3. 40 Mcg
12. Recombinant Teriparatide for Injection Market, by Indication
12.1. Introduction
12.2. Glucocorticoid Induced Osteoporosis
12.3. Hypoparathyroidism
12.4. Severe Osteoporosis
12.2. Glucocorticoid Induced Osteoporosis
12.3. Hypoparathyroidism
12.4. Severe Osteoporosis
13. Americas Recombinant Teriparatide for Injection Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Recombinant Teriparatide for Injection Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Recombinant Teriparatide for Injection Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eli Lilly and Company
16.3.2. Sandoz International GmbH
16.3.3. Teva Pharmaceutical Industries Limited
16.3.4. Dr. Reddy's Laboratories Limited
16.3.5. Natco Pharma Limited
16.3.6. Viatris Inc.
16.3.7. Wockhardt Limited
16.3.8. Cipla Limited
16.3.9. Lupin Limited
16.3.10. Intas Pharmaceuticals Limited
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eli Lilly and Company
16.3.2. Sandoz International GmbH
16.3.3. Teva Pharmaceutical Industries Limited
16.3.4. Dr. Reddy's Laboratories Limited
16.3.5. Natco Pharma Limited
16.3.6. Viatris Inc.
16.3.7. Wockhardt Limited
16.3.8. Cipla Limited
16.3.9. Lupin Limited
16.3.10. Intas Pharmaceuticals Limited
List of Figures
FIGURE 1. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET: RESEARCHAI
FIGURE 26. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET: RESEARCHSTATISTICS
FIGURE 27. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET: RESEARCHCONTACTS
FIGURE 28. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET: RESEARCHAI
FIGURE 26. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET: RESEARCHSTATISTICS
FIGURE 27. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET: RESEARCHCONTACTS
FIGURE 28. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRE-FILLED PEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRE-FILLED PEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOMECARE SETTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOMECARE SETTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY 20 MCG, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY 20 MCG, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY 40 MCG, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY 40 MCG, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY GLUCOCORTICOID INDUCED OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY GLUCOCORTICOID INDUCED OSTEOPOROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HYPOPARATHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HYPOPARATHYROIDISM, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY SEVERE OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY SEVERE OSTEOPOROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 70. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 71. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 76. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 77. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 78. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 79. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 86. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 87. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 132. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 133. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 138. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 139. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 148. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 149. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 168. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 169. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 172. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 173. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 178. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 179. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 218. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 219. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 232. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 233. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 238. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 239. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 248. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 249. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 278. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 279. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. TURKEY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 282. TURKEY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 283. TURKEY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. TURKEY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. TURKEY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. T
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRE-FILLED PEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRE-FILLED PEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOMECARE SETTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOMECARE SETTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY 20 MCG, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY 20 MCG, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY 40 MCG, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY 40 MCG, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY GLUCOCORTICOID INDUCED OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY GLUCOCORTICOID INDUCED OSTEOPOROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HYPOPARATHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY HYPOPARATHYROIDISM, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY SEVERE OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY SEVERE OSTEOPOROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 70. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 71. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 76. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 77. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 78. CANADA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 79. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 86. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 87. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. MEXICO RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 132. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 133. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 138. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 139. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. GERMANY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 148. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 149. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. FRANCE RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 168. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 169. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. ITALY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 172. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 173. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 178. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 179. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. SPAIN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 218. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 219. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. DENMARK RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 232. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 233. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 238. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 239. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. QATAR RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 248. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 249. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. FINLAND RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 278. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 279. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. EGYPT RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. TURKEY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 282. TURKEY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 283. TURKEY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. TURKEY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. TURKEY RECOMBINANT TERIPARATIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. T
Samples
LOADING...
Companies Mentioned
The companies profiled in this Recombinant Teriparatide for Injection Market report include:- Eli Lilly and Company
- Sandoz International GmbH
- Teva Pharmaceutical Industries Limited
- Dr. Reddy's Laboratories Limited
- Natco Pharma Limited
- Viatris Inc.
- Wockhardt Limited
- Cipla Limited
- Lupin Limited
- Intas Pharmaceuticals Limited
